Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05429632 · ClinicalTrials.gov registry record · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
A Phase 3 study of Adult Acute Myeloid Leukemia, sponsored by Priothera SAS.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 366
- Enrollment target
- 20
- Study locations
NCT05429632: Recruiting Phase 3 study of Adult Acute Myeloid Leukemia, sponsored by Priothera SAS.
NCT05429632 is a Phase 3 study of Adult Acute Myeloid Leukemia that is actively recruiting participants, run by Priothera SAS. The registered enrollment target is 366 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05429632, a Phase 3 study of Adult Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Priothera SAS.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 366 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Primary Outcome
To compare the efficacy of mocravimod to that of placebo
Conditions Studied
Interventions
- DRUG mocravimod
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte - Duarte
- University of California Los Angeles (UCLA) - David Geffen School of Medicine - Los Angeles
Michigan
- Henry Ford Cancer Institute - Detroit
- Spectrum Health Medical Group (SHMG) - Blood & Marrow Transplant - Adult (BMT) - Grand Rapids
New York
- University of Rochester Medical Center (URMC) - Rochester
- Stony Brook University (SBU) - Cancer Center - Stony Brook
Ohio
- University of Cincinnati Medical Center (University Hospital) - Cincinnati
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - Cleveland
Alabama
- University of Alabama Hospital (UAB Hospital) - Birmingham
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Colorado
- UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center - Aurora
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2022-06-16 |
| Est. Completion | 2029-11 |
| Phase | Phase 3 |
What NCT05429632 shows while recruiting
NCT05429632 is an interventional study that assigns participants to a tested intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Adult Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which mocravimod is the first listed.
NCT05429632 names 20 study sites across 16 states, led by California, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT05429632 about?
NCT05429632 is a clinical study titled "Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT". This is a multi-center, randomized, double-blinded, placebo controlled trial.
What is the current status of trial NCT05429632?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 2022-06-16. Estimated completion is 2029-11.
What conditions does trial NCT05429632 study?
This clinical trial studies the following conditions: Adult Acute Myeloid Leukemia.
What interventions are being tested in trial NCT05429632?
The interventions under investigation include: mocravimod (DRUG).
Who is sponsoring clinical trial NCT05429632?
This trial is sponsored by Priothera SAS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05429632 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05429632's enrollment target sits among peer trials
366 1000th of 2000 higher than 1,000 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05083481 · 366 participants · Phase 1
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT06979453 · 366 participants · Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI